Summary
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
Description
THE PHARMACEUTICAL MARKET: SERBIA - REVIEW
The Serbian pharmaceutical market is one of the poorest in the region in per capita terms, with spending similar to that found in Romania. However, the market is predicted to record a high growth rate over the next few years. The market is driven by strong import growth, although a decline was recorded in 2009. Continued economic recovery in 2011 will help to boost the expansion of the Serbian pharmaceutical market. In 2011, Serbia will have the highest level of healthcare expenditure in the region, in terms of the percentage of GDP spent on health. Most health spending is in the public sector, channelled through the obligatory health insurance system. The proportion of private sector spending is expected to grow steadily between 2011 and 2016.
The largest Serbian pharmaceutical manufacturers are Galenika, Hemofarm, Zdravlje and Zorka, which together account for around 90% of domestic drug production. Most companies are privately-owned. Foreign manufacturers are slowly increasing their presence in the country. At the end of 2010, the Serbian subsidiary of PharmaSwiss started the construction of a pharmaceutical manufacturing unit in Belgrade, which will allow it to extend its operations in Serbia from mainly repackaging and distribution, to end-to-end manufacturing. In June 2010, Galenika opened a new solid pharmaceutical factory, which will assist the company in becoming a regional leader in the sector.
In 2009, Serbian pharmaceutical trade was affected by the global economic downturn, with both imports and exports registering notable decreases; this resulted in a substantial decline in the trade deficit. Pharmaceutical exports are of low value, although figures have risen in recent years. Import growth was strong until 2009; double-digit growth is not expected to return until domestic demand reaches pre-recession levels. Over three quarters of imports and almost all exports were in finished medicament form in 2009.
ENHANCED STRATEGIC INTELLIGENCE
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
HEALTHCARE STATISTICS
A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.
The Pharmaceutical Market: Serbia published by Espicom Business Intelligence in January 31, 2013. This report consists of 100 Pages and the price starts from US $ 1295.
The contents of this page may be different from the latest version. Please contact us for details.
